|
Title
|
Publication Date
|
Price
|
Relevance
|
Wyeth
SWOT Analysis
|
Jun 2009 |
£79 |
100% |
|
Wyeth: PharmaVitae Model
|
Jan 2009 |
£3,605 |
99% |
|
Wyeth: Corporate Analysis
|
May 2008 |
£255 |
99% |
|
Wyeth - OTC Healthcare - World
|
Dec 2008 |
£245 |
99% |
|
Wyeth OTC Healthcare World
|
Jan 2008 |
£195 |
99% |
|
Wyeth: Pipeline Products Performance Potential
|
Mar 2008 |
£595 |
98% |
|
Wyeth - Financial and Strategic Analysis Review
|
Apr 2009 |
£79 |
97% |
|
Wyeth: PharmaVitae Profile
|
Mar 2009 |
£3,605 |
96% |
|
Clinical Nutrition Products
|
Apr 2010 |
£2,815 |
88% |
|
Anti Infectives, Vol II: Antibacterials
|
Apr 2007 |
£1,895 |
86% |
Mergers and Aquisitions in the Pharmaceuticals Sector, 2009
Critical success factors for competing in a consolidating market
|
Apr 2009 |
£995 |
86% |
|
Hormone Replacement Therapy (HRT)
|
Sep 2011 |
£2,655 |
84% |
|
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
|
Aug 2008 |
£4,805 |
84% |
|
NBTY Inc OTC Healthcare World
|
Jan 2008 |
£195 |
84% |
|
Merck KGaA OTC Healthcare World
|
Jan 2008 |
£195 |
83% |
|
Health and Wellness - Nutritionals - Pakistan
|
Mar 2009 |
£800 |
83% |
Ablynx NV - Pharmaceuticals & Healthcare
Deals and Alliances Profile
|
Jul 2009 |
£160 |
82% |
|
The Recession and its impact on Pharamceutical M&A Activity
|
Sep 2009 |
£495 |
82% |
Thrombocytopenia Global Clinical Trials Review
Q1, 2011
|
Apr 2011 |
£630 |
81% |
|
Eye Care in United States
|
May 2006 |
£450 |
81% |
Coagulation Factors 2009
Target Pipeline and Corporate Benchmark Analysis
|
Aug 2009 |
£2,035 |
81% |
CNS Market Trends, 2007 to 2010
Key Market Forecasts and Growth Opportunities
|
Jun 2007 |
£995 |
81% |
|
Wound Treatments in China
|
Sep 2009 |
£560 |
81% |
|
Digestive Remedies in United States
|
May 2006 |
£450 |
81% |
|
Medicated Skin Care in United States
|
May 2006 |
£450 |
80% |
|
NRT Smoking Cessation Aids in United States
|
May 2006 |
£450 |
80% |
|
Smoking Cessation Aids in Ireland
|
Jan 2006 |
£450 |
80% |
|
Vitamins And Dietary Supplements in United States
|
May 2006 |
£450 |
79% |
Pharmaceutical Product Approval Trends, 2007
Key Market Benchmarks And Strategic Insights
|
Dec 2007 |
£1,299 |
79% |
Curis, Inc. – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
79% |
